Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Bioxcel Therapeutics ( (BTAI) ) just unveiled an announcement.
On December 12, 2025, BioXcel Therapeutics held its annual stockholders meeting where 44.68% of the company’s outstanding common stock was represented. During the meeting, three Class I directors were elected, and several proposals were approved, including the appointment of Ernst & Young LLP as the independent auditor, executive compensation, a potential reverse stock split, and authorization for meeting adjournments if necessary.
The most recent analyst rating on (BTAI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.
Spark’s Take on BTAI Stock
According to Spark, TipRanks’ AI Analyst, BTAI is a Underperform.
Bioxcel Therapeutics’ stock is rated at the lowest end of the scale due to substantial financial instability, including ongoing losses, high debt, and negative cash flows. Short-term technical indicators and valuation metrics further highlight the current challenges. The company needs to address these financial and operational issues to improve its stock performance.
To see Spark’s full report on BTAI stock, click here.
More about Bioxcel Therapeutics
BioXcel Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of innovative medicines for neurological and immuno-oncology disorders.
Average Trading Volume: 899,573
Technical Sentiment Signal: Sell
Current Market Cap: $43.96M
See more insights into BTAI stock on TipRanks’ Stock Analysis page.